Journal Article

A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine

Martinón-Torres, Federico, Watson, Wendy, Giardina, Peter C., Trammel, James, Drozd, Jelena, Bickham, Kara, Gruber, William C., Tamimi, Noor, Martinez, Silvina Natalini, Peng, Yahong, Kline, Mary J.

2025

Overview

This phase 3, randomized, partially double-blind study investigated the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine (PCV20) in healthy toddlers ≥12–<24 months of age who had previously received 2 infant doses of 13-valent PCV (PCV13). Participants were randomized to receive 1 or 2 doses of PCV20 (the second dose was administered 56–70 days after the first dose), or 1 dose of PCV13. The primary pneumococcal immunogenicity endpoint was the percentages of participants with predefined serotype-specific immunoglobulin G (IgG) concentrations (≥0.35 μg/mL) for the 7 additional serotypes 1 month after the last vaccination. Percentages of participants with predefined IgG concentrations for the 13 matched serotypes, IgG geometric mean concentrations, and opsonophagocytic activity (OPA) geometric mean titers were also evaluated for all 20 vaccine serotypes. Safety endpoints included local reactions, systemic events, adverse events, and serious adverse events. Overall, 356 participants were randomized (2-dose PCV20, n = 121; 1-dose PCV20, n = 118; PCV13, n = 117). One month after 1 PCV20 dose, ≥75.9 % of participants had IgG concentrations ≥0.35 μg/mL for all 7 additional serotypes, except serotype 12F (54.6 %). After 2 PCV20 doses, the percentage of participants with IgG concentrations ≥0.35 μg/mL for the 7 additional serotypes was ≥91.2 %. PCV20 elicited IgG and OPA responses for all 20 serotypes including serotype 12F. IgG distributions were well differentiated and substantially higher in PCV20 groups than the PCV13 group for the 7 additional serotypes, and generally similar between all groups for the 13 matched serotypes. In conclusion, a single toddler dose of PCV20 after 2 infant PCV13 doses elicited immune responses expected to help provide protection against the 7 additional serotypes and to provide similar protection against the 13 matched serotypes as PCV13. These data support a transition from PCV13 to PCV20 at the toddler dose. The safety and tolerability profile of PCV20 was similar to PCV13. Trial registration:Clinicaltrials.gov, NCT05408429. •PCV20 safety, tolerability, and immunogenicity in healthy toddlers was investigated.•Participants had previously received 2 infant doses of PCV13.•PCV20 single toddler dose expected to help protect against 7 additional serotypes.•PCV20 expected to provide similar protection as PCV13 against 13 matched serotypes.•The safety/tolerability profile of PCV20 toddler doses was similar to PCV13.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: 20-valent pneumococcal conjugate vaccine / Adverse events / Age / Allergy and Immunology / Antibodies, Bacterial - blood / Babies / Conjugates / Double-Blind Method / Female / Guardians / Humans / IgG antibody / Immune response / Immunization / Immunization Schedule / Immunogenicity / Immunogenicity, Vaccine / Immunoglobulin G / Immunoglobulin G - blood / infancy / Infant / Infants / International organizations / Male / PCV20 / Pediatrics / Pneumococcal Infections - immunology / Pneumococcal Infections - prevention & control / Pneumococcal Vaccines - administration & dosage / Pneumococcal Vaccines - adverse effects / Pneumococcal Vaccines - immunology / Safety / Serogroup / Serotypes / Streptococcus infections / Streptococcus pneumoniae / Streptococcus pneumoniae - immunology / Toddlers / Vaccination / Vaccines / Vaccines, Conjugate - administration & dosage / Vaccines, Conjugate - adverse effects / Vaccines, Conjugate - immunology